Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.M's Science Corporation, or MSC, a clinical stage discovery and development company, has initiated a Phase II study in Europe with its lead product SA4503 for treatment of stroke.
Subscribe to our email newsletter
This latest Phase II trial is an international, multi-center, double-blind and placebo-controlled study of SA4503 in patients with stroke with a planned enrollment of approximately 60 patients. The primary objective of the study is to evaluate safety of SA4503 in this patient population.
SA4503 is a potent and selective agonist of the sigma-1 receptor that is associated with enhancement of recovery in experimental models of stroke. SA4503 induces neuroregeneration and facilitates the recovery of damaged tissues from stress or ischemia-induced insults.
Shiro Mita, chairman and CEO of MSC, said: “Stroke poses significant therapeutic challenges. SA4503 with its unique and unexploited mechanism has the potential to address the limitations of today’s stroke therapies.”